Dong-Lin Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dong-Lin Liang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Qi Shi
National Key-Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, NHC Key Laboratory of Medical Virology and Viral Diseases, Chinese Center for Disease Control and Prevention, National Institute for Viral Disease Control and Prevention, Beijing, China
3 shared publications - Bing Xu
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Chinese Academy of Preventive Medicine, Beijing 102206, China
2 shared publications - Cao Chen
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory for Medical Virology and Viral Diseases, Beijing Key Laboratory of Viral Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing 102206, China
2 shared publications - Ju-Zheng Li
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Chinese Academy of Preventive Medicine, Beijing 102206, China
2 shared publications - Liping Gao
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory for Medical Virology and Viral Diseases, Beijing Key Laboratory of Viral Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing 102206, China
2 shared publications - Ruhan A
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine Beijing China
2 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (11) , 2491
Scrapie, Bovine Spongiform Encephalopathy and Chronic Wasting Disease: Current Status, Control Measures and Human Health Implications
Animal prion diseases mainly include scrapie in sheep and goats, bovine spongiform encephalopathy (BSE) in cattle, and chronic wasting disease (CWD) in cervids. Long-term epidemiological and experimental studies indicate that CWD appears non-zoonotic, whereas the zoonotic risk of scrapie remains to be fully clarified, while BSE is responsible for the emergence of a new-type human prion disease, variant Creutzfeldt–Jakob disease (vCJD). Peak BSE cases exceeded 35,000 per year in the UK during 1992–1993; vCJD peaked at 29 cases in 2000; approximately 200,000 BSE cattle have been reported worldwide; 233 vCJD cases have been recorded globally; and CWD had been detected in 36 US states and five Canadian provinces by 2025. In this review, disease histories, control and eradication measures, and current prevalences of those animal prion diseases are analyzed. Following decades of active surveillance and rigorous control measures, the potential impact of BSE on human health has been reduced to a negligible level, and the impact of scrapie on animal health has likewise remarkably decreased. Conversely, CWD displays an expanding geographical trend across North America and Northern Europe, imposing a substantial burden on animal health of both captive and free-ranging cervids.
- 1 November 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (11) , 2491
Open AccessScrapie, Bovine Spongiform Encephalopathy and Chronic Wasting Disease: Current Status, Control Measures and Human Health Implications
Animal prion diseases mainly include scrapie in sheep and goats, bovine spongiform encephalopathy (BSE) in cattle, and chronic wasting disease (CWD) in cervids. Long-term epidemiological and experimental studies indicate that CWD appears non-zoonotic, whereas the zoonotic risk of scrapie remains to be fully clarified, while BSE is responsible for the emergence of a new-type human prion disease, variant Creutzfeldt–Jakob disease (vCJD). Peak BSE cases exceeded 35,000 per year in the UK during 1992–1993; vCJD peaked at 29 cases in 2000; approximately 200,000 BSE cattle have been reported worldwide; 233 vCJD cases have been recorded globally; and CWD had been detected in 36 US states and five Canadian provinces by 2025. In this review, disease histories, control and eradication measures, and current prevalences of those animal prion diseases are analyzed. Following decades of active surveillance and rigorous control measures, the potential impact of BSE on human health has been reduced to a negligible level, and the impact of scrapie on animal health has likewise remarkably decreased. Conversely, CWD displays an expanding geographical trend across North America and Northern Europe, imposing a substantial burden on animal health of both captive and free-ranging cervids.
- Open Access
- 24 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9524
Inhibition of miR-148a-3p Ameliorates Prion Accumulation by Restoring ATP6AP2-Mediated Lysosomal Acidification
Prion diseases (PrDs) are fatal neurodegenerative disorders characterized by the accumulation of misfolded prion protein (PrPSc) and progressive impairment of protein quality-control systems. Lysosomal dysfunction and defective autophagic flux contribute to PrPSc accumulation, but the upstream regulatory mechanisms remain incompletely defined. In this study, we investigated the regulatory role of miR-148a-3p during prion infection. We found that miR-148a-3p expression is markedly increased in ME7- and 139A-infected mouse brains and prion-infected SMB-S15 cells. Dual-luciferase assays confirmed that miR-148a-3p directly targets the PRNP 3′UTR, negatively regulating cellular PrP expression. In prion-infected cells, inhibition of miR-148a-3p reduced proteinase K (PK)-resistant PrP (PrPres), delayed RT-QuIC conversion, and decreased PMCA-amplified PrPres. Through bioinformatic prediction and experimental validation, we identified ATP6AP2, a V-ATPase-associated regulator of lysosomal acidification, as a high-confidence target of miR-148a-3p. ATP6AP2 expression was significantly decreased in sCJD transcriptomic data, scrapie-infected mouse brains, and prion-infected cells. Importantly, inhibition of miR-148a-3p restored ATP6AP2 expression, which improved lysosomal acidification and alleviated impaired autophagic flux. Furthermore, overexpression of ATP6AP2 directly reduced PrPSc accumulation in SMB-S15 cells and diminished prion seeding capacities in RT-QuIC and PMCA assays. These findings identify miR-148a-3p as an upstream regulator of ATP6AP2-dependent lysosomal dysfunction in prion infection. Inhibition of miR-148a-3p may restore lysosomal clearance capacity and reduce PrPSc accumulation, suggesting a potential regulatory strategy for PrDs.
- 24 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9524
Open AccessInhibition of miR-148a-3p Ameliorates Prion Accumulation by Restoring ATP6AP2-Mediated Lysosomal Acidification
Prion diseases (PrDs) are fatal neurodegenerative disorders characterized by the accumulation of misfolded prion protein (PrPSc) and progressive impairment of protein quality-control systems. Lysosomal dysfunction and defective autophagic flux contribute to PrPSc accumulation, but the upstream regulatory mechanisms remain incompletely defined. In this study, we investigated the regulatory role of miR-148a-3p during prion infection. We found that miR-148a-3p expression is markedly increased in ME7- and 139A-infected mouse brains and prion-infected SMB-S15 cells. Dual-luciferase assays confirmed that miR-148a-3p directly targets the PRNP 3′UTR, negatively regulating cellular PrP expression. In prion-infected cells, inhibition of miR-148a-3p reduced proteinase K (PK)-resistant PrP (PrPres), delayed RT-QuIC conversion, and decreased PMCA-amplified PrPres. Through bioinformatic prediction and experimental validation, we identified ATP6AP2, a V-ATPase-associated regulator of lysosomal acidification, as a high-confidence target of miR-148a-3p. ATP6AP2 expression was significantly decreased in sCJD transcriptomic data, scrapie-infected mouse brains, and prion-infected cells. Importantly, inhibition of miR-148a-3p restored ATP6AP2 expression, which improved lysosomal acidification and alleviated impaired autophagic flux. Furthermore, overexpression of ATP6AP2 directly reduced PrPSc accumulation in SMB-S15 cells and diminished prion seeding capacities in RT-QuIC and PMCA assays. These findings identify miR-148a-3p as an upstream regulator of ATP6AP2-dependent lysosomal dysfunction in prion infection. Inhibition of miR-148a-3p may restore lysosomal clearance capacity and reduce PrPSc accumulation, suggesting a potential regulatory strategy for PrDs.
- Open Access
- 9 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (4) , 1678
High Proportions of GAP43 Positivity in the Cerebrospinal Fluids of Patients with Sporadic and Certain Types of Genetic Creutzfeldt-Jakob Diseases by Western Blot Analysis
Growth-associated protein-43 (GAP43) is a neuronal protein essential for synaptic function and plasticity, and its reduction has been observed in brains of prion diseases (PrDs) and rodent models. However, its status in the cerebrospinal fluid (CSF) of patients with PrDs remains unclear. CSF samples from 140 PrD cases, including 48 sCJD, 35 T188K-gCJD, 22 E200K-gCJD, 35 D178N-FFI, and 36 non-PrD controls, were analyzed for GAP43 by Western blot. The results were compared with 14-3-3 and calmodulin (CaM) detected by WB, and associated with clinical features. GAP43 positivity was significantly higher in sCJD (70.83%), T188K-gCJD (65.71%), and E200K-gCJD (72.73%) than in non-PrD controls (27.78%). The sensitivity and specificity of GAP43 (around 70–75%) were comparable to 14-3-3 and CaM, though inferior to RT-QuIC and total tau reported elsewhere. CSF GAP43 positivity correlated with sCJD-associated MRI changes, periodic sharp-wave complexes (PSWC) on EEG, and with 14-3-3 and CaM positivity. Our data here indicate the feasibility of usage of GAP43 by Western blot analysis as a diagnostic, at least as a screening, biomarker for sCJD and certain types of gPrDs.
- 9 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (4) , 1678
Open AccessHigh Proportions of GAP43 Positivity in the Cerebrospinal Fluids of Patients with Sporadic and Certain Types of Genetic Creutzfeldt-Jakob Diseases by Western Blot Analysis
Growth-associated protein-43 (GAP43) is a neuronal protein essential for synaptic function and plasticity, and its reduction has been observed in brains of prion diseases (PrDs) and rodent models. However, its status in the cerebrospinal fluid (CSF) of patients with PrDs remains unclear. CSF samples from 140 PrD cases, including 48 sCJD, 35 T188K-gCJD, 22 E200K-gCJD, 35 D178N-FFI, and 36 non-PrD controls, were analyzed for GAP43 by Western blot. The results were compared with 14-3-3 and calmodulin (CaM) detected by WB, and associated with clinical features. GAP43 positivity was significantly higher in sCJD (70.83%), T188K-gCJD (65.71%), and E200K-gCJD (72.73%) than in non-PrD controls (27.78%). The sensitivity and specificity of GAP43 (around 70–75%) were comparable to 14-3-3 and CaM, though inferior to RT-QuIC and total tau reported elsewhere. CSF GAP43 positivity correlated with sCJD-associated MRI changes, periodic sharp-wave complexes (PSWC) on EEG, and with 14-3-3 and CaM positivity. Our data here indicate the feasibility of usage of GAP43 by Western blot analysis as a diagnostic, at least as a screening, biomarker for sCJD and certain types of gPrDs.